Bevegelser i dag👍

👀👀

https://www.alliedmarketresearch.com/penicillin-drug-market-A110795

https://www.dagensmedisin.no/debatt-og-kronikk/norskutviklet-teknologi-mot-antibiotikaresistens/280616

den perfekte storm
https://www.globenewswire.com/en/news-release/2023/07/12/2703710/0/en/Penicillin-Drug-Market-to-reach-12-1-Billion-globally-by-2032-at-3-7-CAGR-Allied-Market-Research.html?utm_source=chatgpt.com
Det globale markedet for penicillin er betydelig og forventes å vokse i årene som kommer. Ifølge en rapport fra Allied Market Research, var markedet verdt 8,4 milliarder dollar i 2022 og forventes å nå 12,1 milliarder dollar innen 2032, med en årlig vekst på 3,7 % fra 2023 til 2032. ​
GlobeNewswire

En annen analyse indikerer at penicillinmarkedet vil vokse fra 10,38 milliarder dollar i 2023 til 12,16 milliarder dollar innen 2028, med en årlig vekst på 3,21 % i perioden 2023–2028. ​
stringentdatalytics.com

Disse estimatene reflekterer en stabil vekst i etterspørselen etter penicillin, drevet av økt bevissthet om kombinasjonsbehandlinger, høyere forekomst av bakterielle infeksjoner og tilgjengeligheten av generiske legemidler. Imidlertid kan utfordringer som antibiotikaresistens påvirke markedets utvikling i fremtiden.

Soon proof-of-concept and multibillion-dollar cap. Bigpharma

This stock will soon make you richer than you ever dreamed

Next steps for SBE-01
Having demonstrated early proof-of-concept for the SBE project and in accordance with the company's corporate strategy, SoftOx will seek a strategic partner to further develop and advance its wound care segment within acute and chronic indications.

gammel tråd fra 2021 - ja det var noe å dra frem

It is highly relevant now.

TOP50 liste er på vei 🔥I dag skal alle inn i softox 🚀🚀

Kan bli en hot aksje dette

Hot er helt riktig.
TOP50 , det holdes på aksjene etter at flere har økt kraftig siste uken. The potential is so huge, no one above and no one next to it. Stay tuned because big things are happening soon 《 Proof of consept》. Almås øker ikke med 115 millioner aksjer på gøy.

Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 7.04.2025

01 PRO AS 13.61% 11.52m 265.6m
02 ALMHAUG BOLIG AS 9.95% 8 426.1k 194.2m
03 OSLO NÆRINGSUTVIKLING AS 8.13% 6 886.2k 158.7m
04 J G INVEST AS 4.84% 4 098.2k 94.43m
05 HAREFRØKEN INVEST AS 4.80% 4 063.5k 93.63m
06 BONICA AS 4.37% 3 696.7k 85.18m
07 NORDNET LIVSFORSIKRING AS 2.87% 2 432.3k 56.04m -565.2k
08 DANSKE BANK A/S 2.54% 2 150.4k 49.55m
09 STIFTELSEN UNI 2.44% 2 068.2k 47.66m
10 LOYD AS 2.12% 1 792.5k 41.3m
11 NORDNET BANK AB 1.97% 1 668.6k 38.45m ++++1 226k
12 AUBERT INVEST AS 1.89% 1 604.3k 36.97m
13 ALMÅS INGEBORG VICTORIA AARSVOLD 1.83% 1 549.2k 35.7m
14 WL-02 HOLDING AS 1.57% 1 330.5k 30.66m
15 HOLTA & CO. AS 1.45% 1 224.4k 28.21m
16 GH HOLDING AS 1.30% 1 099k 25.32m
17 GEMALLO AS 1.28% 1 084.3k 24.98m
18 ARJO BYGG AS 0.90% 759.5k 17.5m
19 BØRSELIEN MARIUS 0.89% 752.02k 17.33m
20 THE BANK OF NEW YORK MELLON SA/NV 0.85% 716.79k 16.52m
21 RONGVED PÅL 0.83% 705.25k 16.25m
22 IHLEN HELENE KRISTINE 0.76% 645.63k 14.88m
23 WL-01 HOLDING AS 0.72% 607.6k 14m
24 RESULTING AS 0.67% 571.5k 13.17m
25 S FJORD INVEST AS 0.51% 434k 10m
26 JONASSEN ULF EUGEN 0.51% 431.18k 9 935k
27 HARSTAD JOHAN CHRISTIAN 0.51% 429.66k 9 900k
28 SONJA OG EMIL AUBERTS LEGAT STI 0.48% 404.02k 9 309k
29 BØRSELIEN HELGE STEINAR 0.47% 394.94k 9 100k
30 ROKINA ALENA 0.40% 342.86k 7 900k
31 AVANZA BANK AB MEGLERKONTO 0.40% 339.85k 7 831k ++++21 335
32 HANDELAND ØYVIND 0.38% 325.5k 7 500k
33 FAGERBAKKE JOHN TERJE 0.36% 303.8k 7 000k
34 INNSELSET-SMIDTSRØD SANDER 0.36% 301.15k 6 939k
35 RUTEN AS 0.33% 275.76k 6 354k
36 STORM-JOHANNESSEN PÅL 0.32% 273.69k 6 306k
37 AASHEIM STEINAR 0.31% 260.4k 6 000k
38 GEHITO AS 0.31% 260.4k 6 000k +++++1 986k
39 ZAPFFE AUDUN 0.29% 248.97k 5 737k
40 LITLESKARE KENNETH 0.28% 238.7k 5 500k
41 HOVIND SVENN IDAR FORBERGSKOG 0.26% 221.24k 5 098k
42 NILSEN SIMEN NESTOR 0.26% 217k 5 000k
43 KJELSRUD JOHN-EGIL 0.23% 192.01k 4 424k
44 ADVOKATFIRMA SYVERTSEN AS 0.22% 187.47k 4 320k
45 NORDEA BANK ABP 0.21% 174.44k 4 019k
46 RWL HOLDING AS 0.20% 173.6k 4 000k
47 WIK LEIF MAGNE 0.19% 162.75k 3 750k
48 ALI AHMED HARUUN 0.18% 156.05k 3 596k
49 HASSELEID WRÅL MAGNE 0.18% 152.43k 3 512k ++++36 000
50 PERFORMAX AS 0.17% 141.8k 3 267k

Hvor henter du oplysninger på top50 ?
På selskabets hjemmeside kan man jo ikke se disse oplysninger - kun top10 så vidt jeg husker.

PÅ de åpne investorlistene. 2 dager gamle.

Tak - har du et link hertil?

Har fundet stedet og har tilmeldt listen.

Stikker videre nå.

Veldig spennende nå.. steg mye på slutten idag med et par feite kjøp. Bygger momentum nå novo guttene

Er der nogen, som har set tegn på, at NOVO kan være interesseret i selskabet?

Det er en tydelig link der ja.. hvordan tolker dere kjøpet på 115 millioner aksjer av Kristian Almås…?

Ser meget lovende ut.

Soft ox er interessant av flere grunner - men også fordi denne typen aksjer er bra aksjer i tider hvor markedet opplever svingninger- da er helse aksjer typ soft ox spennende.

Får vi et gjennombrudd nå

Hei Stjerna! Er du og Gullhaugen en og samme person? I alle fall like artig å lese de kraftfulle innleggene dine som det Gullet kommer med. Når det gjelder aksjen, så ser det ikke så lystig ut i dag - som med resten av børsen. Da er det godt at du i alle fall er ultrapositiv og gir oss andre håp 🙏

Du får ha lykke til. Jeg har troa.

Jo mere man leser jo om soft ox desto mer tro

skal vi få 10-50øre snart, rally i USA.

Moving day..!

stikker denne snart 6øre

10øre kommer i dag.

Softox den forsvunne diamant
Investornytt av Investornytt

Drahjelp fra investor nytt i dag👍

Rally🌞🌞🌞🌞

Ser vi 8 til 10 i morgen?

US ARMY GOES FOR FDA APPROVAL WITH SOFTOX IN THE USA. WHAT DOES IT MEAN? BIG Biopharma deal

Spenningen stiger aksjen kan gå fort opp mot 50 nå, enrom handel i dag.

Tipper denne vil gå enormt i tiden framover.

Lykke til.

Snart klart for avgang oppover, rekyl aksje soft ox nå🔥

SoftOx SolutionsSoftOx Solutions


ABOUT US
A pharmaceutical company
SoftOx Solutions AS (SoftOx, listed at Euronext Growth Oslo) is a clinical-stage pharmaceutical company based in Oslo, Norway. We have developed a non-toxic and highly efficient antimicrobial technology designed to address some of the world’s greatest health challenges, including:

01
Targeting airway infections with endogenous molecule
The SoftOx technology stabilizes an endogenous pan-antimicrobial molecule (HOCl) thereby enhancing one of the immune system’s ways of eradicating pathogens in the airways.
02
Alleviating antimicrobial resistance (AMR) development
As HOCl’s mode of action is unspecific and metabolic independent, no resistance develops when using SoftOx technology. According to the World Health Organization, AMR is a major threat to global health. New forms of resistance are emerging and can spread with remarkable speed between continents. Therefore, the SoftOx technology is likely highly important to counteract this detrimental development.
03
VAP and chronic infections
SoftOx Inhalation Solution (SIS) is effective against pathogens causing VAP as well as other airway infections/pneumonia. With inhaled administration of the nebulized SIS, the treatment will be local, tolerable and is expected to be highly effective.
04
Spread of viruses
Deadly viral outbreaks are expected in the future. There remains an unmet need for effective and well-tolerated virucidal solutions to aid infection prevention and control. SoftOx Inhalation Solution (SIS) has a strong virucidal capacity.
OUR VISION
New ways of eradicating infections
Our vision seemed almost unreachable when SoftOx began work on its formulations 10 years ago. It took plenty of hard work, a strong belief in our research, and a stubbornness to overcome uncertainties, setbacks, and other challenges, and get to where we are today. Thanks to the dedication and commitment of our team, and to the core values we all share, SoftOx is currently in a prime position.

As SoftOx develops into a well-known brand, we will learn to navigate various obstacles. It is therefore important to emphasize that our long-term goals are now within reach, and our ongoing research and development have resulted in greater confidence and optimism than ever before.

Charles Alexandre de Calonne once said: “Nothing is impossible, the impossible just takes a little longer”. This statement corresponds well with our dedication to developing solutions serving human health.


WE ARE COLLABORATING WITH

Leading Research Institutions & Organisations
After years of research and product development
In collaboration With leading Nordic research institutes
SoftOx has developed a non-toxic and highly effective antimicrobial technology, which eradicates and prevents biofilm infections and is fully virucidal.

SoftOx is all about Technology
The unique SoftOx technology, developed in close collaboration with expert scientists and clinicians from the universities in Skåne County and the University of Copenhagen, is based on a combination of naturally occurring chemicals that harbour broad antimicrobial effects without inducing resistance. There is documentation to confirm that this technology has a strong antimicrobial effect against all bacteria (including MRSA), fungi, and viruses tested. Pre-clinical and clinical trials indicate that SoftOx technology is well tolerated. Given its favorable benefit-risk profile, SoftOx technology aims to raise the standards for disinfectants and wound care products.

Developed With Top Ranked Scientists
Aiming to Solve Major Health Challenges

post-image-five


SoftOx Solutions AS is a pharmaceutical company, founded in 2012. After years of research and product development with leading Nordic research institutions, SoftOx has developed a non-toxic and highly efficient pan-antimicrobial technology, which eradicates bacteria, including bacteria in biofilms, and fungi, and is fully virucidal. This technology is in development as a pan-antimicrobial inhaled solution to combat respiratory infections.

Copyright © 2025 SoftOx Solutions. All rights reserved.